Dermatology
Latest News
Frustration over iPLEDGE evident at FDA meeting
Dermatologists argue the iPLEDGE REMS burden is too high for providers and patients. Access problems persist with lockouts and some cite a lack of...
Feature
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
Physicians can respond to pushback from patients on switching to a biosimilar by offering resources and discussing options for both biosimilar and...
Latest News
Limited treatment options exist for brittle nail syndrome
“It’s our duty to warn our patients about the evidence for biotin for treating brittle nails, and about this interference on laboratory tests,” Dr...
Latest News
JAK inhibitor ivarmacitinib shows efficacy for atopic dermatitis in a pivotal trial
The co-primary endpoints were change in IGA and EASI scores at 16 weeks, and both improved rapidly, showing statistical significance relative to...
Latest News
Topical delgocitinib shows promise for chronic hand eczema, pivotal trial shows
Delgocitinib is an investigational topical pan-JAK inhibitor that inhibits activation of the JAK-STAT pathway.
Latest News
Air pollution may be causing eczema
There are now more than three times as many eczema cases as there were in the 1970s, and it now affects as many as 20% of children and 10% of...
News from the FDA/CDC
FDA approves new formulation of Hyrimoz adalimumab biosimilar
The agency approved a higher-concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.
Latest News
Anifrolumab shows promise in refractory discoid lupus erythematosus
Anifrolumab improved symptoms and activity of DLE within 2 months in a study of eight women.
Latest News
New data forecast more oral PDE4 inhibitors for psoriasis
The phase 2b data suggest that the drug, called orismilast, “is a potential new addition to the psoriasis armamentarium,” said Lars E. French, MD...
Conference Coverage
New JAK inhibitor study data confirm benefit in alopecia areata
Deuruxolitinib (CTP-543), an inhibitor of the JAK1 and JAK2 enzymes, has the potential to become the second JAK inhibitor available for the...
Latest News
Pilot study evaluates sensitive skin burden in persons of color
“We were particularly surprised by the high rates of reactivity to skin care products designed for and marketed to those suffering with sensitive...